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Introduction: Salmonella is a typical cause of aortitis, which is associated with high morbidity and mortality. In
infrarenal disease, besides open surgery, endovascular aortic repair as an alternative treatment has been reported.
To the best of our knowledge, we report the first successful endovascular aortic repair documented by necropsy to
date.
Case presentation: A 67-year-old Caucasian man presented with low back pain, fever and positive blood cultures
for Salmonella Enteritidis. A computed tomography scan showed an enlargement and intramural hematoma of the
infrarenal aortic wall; a Salmonella aortitis was suspected and antimicrobial therapy initiated. Because of substantial
comorbidities, endovascular aortic repair was favored over open surgery; postoperatively the antibiotic treatment
was continued for 12 months. Post-mortem there were neither macroscopic nor microscopic signs of aortitis or
graft infection.
Conclusions: We could demonstrate by necropsy that endovascular aortic repair of infrarenal aortitis with
prolonged pre- and postinterventional antibiotic therapy for 12 months was a minimally invasive alternative and
should be considered in selected clinically stable patients with substantial co-morbidities.
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Infectious aortitis is a rare but life-threatening disorder
[1]. Usually a combined strategy of antibiotic treatment
and surgical debridement is required, although no con-
trolled clinical trials have explored its optimal manage-
ment. Despite aggressive therapeutic approaches
mortality remains high [2-7]. An alternative is combined
medical and endovascular management. We report the
case of a patient with aortitis due to Salmonella Enteriti-
dis that was successfully treated with endovascular aortic
repair (EVAR) and antibiotic therapy as confirmed by
autopsy.
Infectious aortitis is an inflammatory process within
the arterial wall caused by microorganisms. As a compli-
cation, microbial arteritis with aneurysm can develop.
Possible mechanisms are septic emboli to the vasa
vasorum, continuous infection from a focus extending to
the arterial wall, direct bacterial inoculation and* Correspondence: esther.baechli@spitaluster.ch
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reproduction in any medium, provided the orbacterial seeding in an existing intimal injury or an ath-
erosclerotic plaque [1]. Typical risk factors are male gen-
der, age over 50 years, diabetes, and pathological
alterations of the aortic wall (most commonly athero-
sclerosis) [1]. The most frequently isolated pathogens
are Salmonella and staphylococcal species [8,9].
Diagnosis is based on the clinical picture, radiographic
imaging, and culture results. Because of the nonspecific
presentation with back pain or abdominal discomfort
and fever, the diagnosis of infectious aortitis requires a
high index of suspicion [5]. Nevertheless, an early diag-
nosis is crucial, because microbial arteritis with
aneurysm is associated with a high rate of rupture and
subsequent mortality if left untreated. Once the diagno-
sis is made, a rapid empirical intravenous antibiotic ther-
apy is important while awaiting microbiological data
from blood cultures [1,2].
Case presentation
A 67-year-old Caucasian man presented to the emergency
department with back and abdominal pain, fever and
malaise. He reported that his wife and granddaughterLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Laboratory values at hospital admission (19 days before EVAR), ten days before EVAR and shortly before the
EVAR with follow-up at discharge and after three, six, 12 and 15 months
Day −19 Day −10 Day 0 Day 9 Three months Six months 12 months 15 months
Admission EVAR Discharge Follow-up
Hb (g/L) 144 121 116 104 92 100 139 116
Leuk (G/L) 10.8 9.7 6.4 4.9 6.9 6.2 8.1 6.6
Thr (G/L) 181 343 312 276 474 259 241 262
CRP (mg/L) 99 81 22 17 <5 <5 <5 7.7
CRP C-reactive protein, EVAR endovascular aortic repair, Hb hemoglobin; Leuk leukocytes; Thr thrombocytes.
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had a history of colorectal cancer with a solitary me-
tastasis (7 × 7.5cm) of the abdominal wall, and previ-
ously underwent aortocoronary bypass surgery and
mitral valve reconstruction. On examination, he was
febrile (38.5°C axillary) with otherwise normal vital
signs. The abdomen was distended with discomfort on
deep palpation with a palpable mass in the abdominal
wall. The lower spine was tender on percussion.
Laboratory tests showed an elevated C-reactive protein
(99mg/L, normal < 10mg/L) with mild leukocytosis
(Table 1). Three out of four pairs of blood cultures grew
Salmonella enterica serotype Enteritidis (serogroup D).
Stool cultures for Salmonella were negative. After exclu-
sion of endocarditis, a computed tomographic (CT) scan
for an endovascular focus showed an intramural
hematoma of the infrarenal aorta (20 x 18 x 6mm) withFigure 1 (a) Sagittal reconstruction of the contrast-enhanced initial co
mycotic aneurysm: eccentric saccular pseudo-aneurysm (arrows) of th
and periaortic soft tissue stranding (arrowheads). (b) 3D-reconstruction
the anatomic location of the aortic stent graft.paraaortic fat stranding as well as atherosclerotic plaques
(Figure 1). Thus, the diagnosis of an infectious aortitis
caused by S. Enteritidis was made and he was treated
with ceftriaxone and ciprofloxacin. Open surgery with
excision of the inflammatory tissue and extra-anatomical
bypass-grafting or in situ reconstruction was not an op-
tion because the colon carcinoma had metastasized dir-
ectly in the potential operation area. Since there was
neither evidence of gross aneurysm nor active bleeding,
he was initially treated with intravenous antibiotics and
after a 16-day course of antimicrobial therapy in the
presence of a stable follow-up documented by computed
tomography (CT) scan, EVAR with the Gore Excluder
(W. L. Gore & Associates GmbH, Putzbrunn, Germany)
was performed.
The post-interventional clinical course was uneventful.
Intravenous antibiotic therapy was continued for anothermputed tomography (CT) scan showing typical appearance of a
e abdominal aorta (arising from a ‘breach’(*) in the aortic wall)
of the postinterventional computed tomography (CT) scan showing
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monotherapy with ciprofloxacin for 12 months.
Repeated computed tomography (CT) scans (after three,
six, 12 and 15 months) and blood analysis (with
leukocyte counts and C-reactive protein) were per-
formed during follow-up (Table 1 and Figure 2).
Four months later (16 months after EVAR) the patient
died of an ileus. Postmortem the macroscopic examin-
ation revealed circumferential atheromatous thickening
of the intima and media due to extensive fibrosis and
sclerosis (Figure 3a). Microscopically, diffuse fibrosis and
sclerosis of the aortic wall in the area of the endoluminal
stent graft was described. These findings were unspecific
but consistent with lapsed aortitis. There were no signs
of residual active or chronic inflammation (Figure 3b).Figure 3 (a) Aorta abdominalis and common iliac arteries with
endoluminal aortic Y-prothesis (Gore Excluder) in situ directly
distal of the ostia of the renal arteries opened from dorsal.
Orifices from left to right: celiac trunc (*), superior mesenteric artery
(**), left renal artery (arrowhead). (b) Haematoxylin and EosinDiscussion
The mortality of infectious aortitis and mycotic
aneurysm is high and depends on rapid diagnostic
workup, location of the diseased artery and type of ther-
apy as well as the underlying condition of the patient
[4]. In the largest case series with combined surgical and
antibiotic treatment, an early mortality of 11% to 36% is
documented [6,7]. Medical management without surgery
is fatal in greater than 90% of cases [10].
Wang et al. [11] reported that 35% of adults above
65 years of age with positive blood cultures for non-
typhoid Salmonella had aortitis. Common risk factors
for invasive non-typhoid salmonellosis are immunodefi-
ciency and solid-organ cancer [12]. Since most patientsFigure 2 A series of abdominal computed tomography (CT)
scan studies from the patient, the first at the time of diagnosis
one week before endovascular aortic repair (EVAR) and regular
follow-up computed tomography (CT) scans one week after
EVAR and after three, six, 12 and 15 months. The initial
intramural hematoma and soft tissue stranding has completely
disappeared three months after EVAR and no signs of persistent or
relapsed infection are detectable on follow up scans. Three months
after discontinuation of antibiotic therapy (15 month after EVAR)
there are no signs of relapse.
staining of a cross-section of the aortic wall showing enhanced
intimal and medial thickening due to fibrosis and atherosclerosis,
but no inflammatory infiltrates.have severe comorbidity an open surgical procedure car-
ries a high perioperative risk [1].
A less invasive approach, namely, combined medical
and endovascular management has been introduced by
Semba et al. [13]. So far, only case reports and small
series of successful EVAR of infectious aortitis have been
reported and reviewed; hence, it is still considered an ex-
perimental procedure [3,6]. Regardless, EVAR has chan-
ged the management of primary mycotic aneurysm over
the last decades [14]. At present, it is probably best
documented for Salmonella infection [15,16].
Based on available data, the early mortality rate asso-
ciated with stent-grafts appears to be lower than the one
associated with conventional surgery. In a recent small
multi-institutional case series, EVAR performed in
selected patients showed a very good outcome with no
in-hospital mortality and only one unrelated late death
[15]. However, late aneurysm-related events including
mortality and complications seem to be more common
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sibility to debride the infectious tissue and the infected
aortic wall [17]. As the majority of late events resulted
from inadequate control of infection, an appropriate pre-
operative antibiotic treatment preferably with clearance
of the bacteremia as well as long-term treatment after
EVAR is mandatory [3,6]. Various factors including ana-
tomic location of the infection (infrarenal, paravisceral,
or thoracic aorta), the nature (fistula versus mycotic
aneurysm), the microbial features, the general condition
and the morbidity of the patient should be considered
before establishing endovascular treatment as a viable
option. It is difficult to define which cases should be
treated endoluminally and it seems that the endovascu-
lar technique should be used only for specific indica-
tions, such as absence of gross purulence, gross
infection, aorto-digestive fistula and uncontrolled sepsis
and in the presence of a high operative risk [16,18].
Our patient had severe comorbidity and there were
neither signs of gross purulence nor fistula. In addition,
he responded rapidly to antibiotic therapy. After five
days the blood cultures turned negative and several
follow-up blood cultures remained negative.
Therefore, we favored an EVAR without delay in this
setting.
The optimal antibiotic agent and duration of treatment
after EVAR remains controversial and some authors rec-
ommend lifelong resumption [15,16]. Prolonged anti-
biotic therapy is generally considered necessary [6]. In
our case, after successful EVAR, an intravenous anti-
biotic therapy was continued for 10 more days. Since at
that time our patient was in a good general condition,
we switched to an oral monotherapy with ciprofloxacin,
which was resumed for a period of 12 months. The dur-
ation of antibiotic therapy was chosen empirically
because simultaneously there was maintenance chemo-
therapy for his colon cancer, which was considered as
immunosuppression. Given normal C-reactive protein,
leukocyte counts, clinical status and negative computed
tomography (CT) the antibiotic therapy was stopped.
In device-associated infections due to gram-negative
rods fluoroquinolones should be favored, because quino-
lones are active against adherent and nongrowing
Escherichia coli [19]. In addition, in an animal model of
implant-associated infection, ciprofloxacin was better
than cotrimoxazole against S. Dublin [20]. Another rea-
son in favor of quinolones is the intracellular bactericidal
activity against non-typhoid Salmonella in vitro as
shown by Chiu et al. [21].
Careful follow-up is of great importance to detect per-
sistent infection, endoleaks and migration of the graft
[1,6]. Our patient underwent CT scans three, six, 12 and
15 months after EVAR and was stable at follow-up with-
out signs of therapy failure (Figure 2).Four months after suspension of antibiotic therapy the
patient died in the course of an ileus. As post-mortem
examination found no evidence of active inflammation
of the aorta or signs of stent failure, one could assume
the patient to be cured of the infection.Conclusions
To conclude, it was shown that EVAR with prolonged
antibiotic treatment with an active antibiotic against ad-
herent bacteria for 12 months can be considered as an
efficacious alternative strategy in appropriate patients
with infectious aortitis due to S. Enteritidis.
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